Enable Biosciences

Enable Biosciences is a South San Francisco-based diagnostics company spun out of UC Berkeley and Stanford in 2016. The company develops ultrasensitive immunoassays for early detection and risk stratification of autoimmune and infectious diseases, with particular expertise in Type 1 Diabetes autoantibody screening and detection. Their ADAP (Advanced Diagnostics for Autoimmune Prediction) technology platform enables predictive medicine through proprietary whole blood autoantibody detection methods. The company partners with leading institutions including Stanford Healthcare, Harvard Medical School, California Department of Public Health, and JDRF, and has performed over 150,000 tests to date. Enable Biosciences' assays support early intervention and clinical decision-making for diabetes risk prediction and population-based screening programs.